-
INCIDENCE AND COSTS OF SECONDARY STROKE EVENTS IN PATIENTS WITH ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK OF NON-CARDIOEMBOLIC ORIGIN
Mar 18, 2026, 21:38 PM -
CUSTOMIZATION OF A LARGE LANGUAGE MODEL APPROACH TO CAPTURE PSA AND IMAGING DERIVED REAL-WORLD PROGRESSION EVENTS IN PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
IMPROVING EARLY DETECTION OF COLORECTAL CANCER THROUGH COMMUNITY PHARMACY ENGAGEMENT: EVIDENCE FROM A SYSTEMATIC REVIEW OF FECAL IMMUNOCHEMICAL TEST-BASED STRATEGIES
Mar 18, 2026, 21:38 PM -
CRITICAL APPRAISAL OF PATIENT ENGAGEMENT FRAMEWORKS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) AND HEALTH TECHNOLOGY ASSESSMENT (HTA)
Mar 18, 2026, 21:38 PM -
DEVELOPING A NOVEL PRO MEASURE IN MULTIPLE GLOBAL REGIONS AND LANGUAGES FOR KEY CONTRACEPTIVE SIDE EFFECTS
Mar 18, 2026, 21:38 PM -
SOCIO-DEMOGRAPHIC DISPARITIES IN HUMAN PAPILLOMAVIRUS VACCINATION AMONG U.S. ADULTS, BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM 2017-2022
Mar 18, 2026, 21:38 PM -
THE POTENTIAL EARLY IMPACT OF THE INFLATION REDUCTION ACT ON BUY-SIDE VALUATION METHODOLOGIES AND TRANSACTION STRUCTURING IN THE PHARMACEUTICAL INDUSTRY
Mar 18, 2026, 21:38 PM -
UNDERSTANDING STAKEHOLDER PERSPECTIVES BETWEEN ENDOVASCULAR AND HYBRID REPAIR FOR THORACIC AORTIC ANEURYSMS AND DISSECTIONS INVOLVING THE LEFT SUBCLAVIAN ARTERY
Mar 18, 2026, 21:38 PM -
PSYCHOMETRIC VALIDATION OF THE QLQ-AA/PNH-54 BASED ON A POOLED DATASET OF A CLINICAL TRIAL AND TWO REAL-WORLD STUDIES OF CROVALIMAB IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Mar 18, 2026, 21:38 PM -
PATHWAYS OF CARE AND ACCESS TO RIFAXIMIN POST-DISCHARGE IN MEDICARE-INSURED PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY
Mar 18, 2026, 21:38 PM -
PERFORMANCE OF ADAPTIVE SMART TAGS IN NESTED KNOWLEDGE FOR AUTOMATED EXTRACTION OF STUDY CHARACTERISTICS
Mar 18, 2026, 21:38 PM -
TRENDS IN PCSK9 INHIBITOR COSTS, COST SHARING, AND ADHERENCE AMONG MEDICARE BENEFICIARIES FOLLOWING 2018 PRICE REDUCTIONS
Mar 18, 2026, 21:38 PM -
SOCIAL MEDIA CONVERSATIONS ON GLP-1 THERAPIES FOR OBESITY: REAL-WORLD EXPERIENCES AND TREATMENT NARRATIVES
Mar 18, 2026, 21:38 PM -
NOVEL PATIENT-CENTERED APPROACH TO CLINICAL TRIAL READINESS IN RARE DISEASES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF INAVOLISIB IN THE TREATMENT OF PIK3A-MUTATED, HR+/HER2-ABC LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN THE US
Mar 18, 2026, 21:38 PM -
A LANDSCAPE ASSESSMENT OF THE STATISTICAL AND ECONOMIC MODELING OF CURE IN ONCOLOGY
Mar 18, 2026, 21:38 PM -
ACCESS TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ANTIOBESITY MEDICATIONS: FORMULARY COVERAGE AND PRIOR AUTHORIZATION RESTRICTIONS ACROSS U.S. PAYERS
Mar 18, 2026, 21:38 PM -
QUANTIFYING CDA-INESSS DIFFERENCES IN ONCOLOGY HTA: RECOMMENDATIONS, RE-ANALYSIS, AND PRICE REDUCTIONS (2024-2025)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF DPYD-GUIDED FOLFOX IN UNRESECTABLE METASTATIC COLORECTAL CANCER IN THE US: A PATIENT-LEVEL MICROSIMULATION MODEL
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE GLOBAL ECONOMIC BURDEN OF HEPATITIS DELTA VIRUS: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM
